KINE 101D
Alternative Names: KINE-101DLatest Information Update: 04 Dec 2023
Price :
$50 *
At a glance
- Originator Kine Sciences
- Class Hepatoprotectants; Obesity therapies; Peptides; Small molecules
- Mechanism of Action Regulatory T-lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 04 Dec 2023 Preclinical trials in Obesity in South Korea (unspecified route), prior to December 2023 (Kine Sciences pipeline, December 2023)
- 04 Jan 2022 Preclinical trials in Non-alcoholic steatohepatitis in South Korea (PO) (Kine Sciences pipeline, January 2022)